Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation

Clofarabine is active in refractory/relapsed acute myeloid leukemia (AML). In this phase 2 study, we treated 18‐ to 65‐year‐old AML patients refractory to first‐line 3 + 7 daunorubicin/cytarabine induction or relapsing after 3 + 7 induction and high‐dose cytarabine consolidation, with clofarabine (3...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Med
Auteurs principaux: Gill, Harinder, Yim, Rita, Pang, Herbert H., Lee, Paul, Chan, Thomas S. Y., Hwang, Yu‐Yan, Leung, Garret M. K., Ip, Ho‐Wan, Leung, Rock Y. Y., Yip, Sze‐Fai, Kho, Bonnie, Lee, Harold K. K., Mak, Vivien, Chan, Chi‐Chung, Lau, June S. M., Lau, Chi‐Kuen, Lin, Shek‐Yin, Wong, Raymond S. M., Li, Wa, Ma, Edmond S. K., Li, Jun, Panagiotou, Gianni, Sim, Joycelyn P. Y., Lie, Albert K. W., Kwong, Yok‐Lam
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2020
Sujets:
Clinical Cancer Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7221314/
https://ncbi.nlm.nih.gov/pubmed/32187883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2865
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires